NORTHWESTERN DEVELOPS TWO NEW INVESTIGATIONAL DRUGS
NU-16CO4 is the second drug developed at Northwestern in pre-clinical research to get authorized by the FDA as an investigational new drug, a complex process that involved a multidisciplinary team of 40 people and 25 offices at Northwestern to set up.
The first drug, NU-0129, combats glioblastoma using spherical nucleic acids to target a gene overexpressed in the cancer, BCL2L12. It’s the result of a collaboration between the laboratories of Alexander Stegh, PhD, assistant professor of Neurology in the Division of Neuro-oncology and of Medicine, and Chad Mirkin, PhD, the George B. Rathmann Professor of Chemistry in the Weinberg College of Arts and Sciences, a professor of Medicine in the Division of Hematology and Oncology and director of Northwestern’s International Institute for Nanotechnology.
The early-stage clinical trial for NU-0129, led by Priya Kumthekar, MD, ’11, ’12 GME, assistant professor of Neurology in Neuro-oncology and of Medicine in Hematology and Oncology, will investigate whether the drug is capable of crossing the blood-brain barrier to reach brain tumors in people.
Stegh, Mirkin, Kumthekar, Chandler, Lesniak and Stupp are all members of the Lurie Cancer Center.